Nutex Health price target lowered to $5 from $6 at Benchmark

Benchmark analyst Bill Sutherland lowered the firm’s price target on Nutex Health to $5 from $6 and keeps a Buy rating on the shares. Nutex “checked all the boxes” in Q1 and even with slower new development is positioned for double digit revenue growth and expanding margins in 2024 and 2025, contends the analyst, who sees “a major disconnect between that outlook” and the stock’s current valuation.